You just read:

STELARA® (ustekinumab) Induced Clinical Response and Remission in Phase 3 Study for the Treatment of Patients with Moderate to Severe Crohn's Disease Who Had Previously Failed or Were Intolerant to Anti-TNF-Alpha Therapy

News provided by

Janssen

18 Mar, 2016, 10:20 GMT